Elite Pharma Net Income
| ELTP Stock | USD 0.42 0.01 2.33% |
As of the 13th of February 2026, Elite Pharma shows the Variance of 15.1, standard deviation of 3.89, and Mean Deviation of 2.44. Elite Pharma technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for Elite Pharma, which can be compared to its peers.
Analyzing historical trends in various income statement and balance sheet accounts from Elite Pharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Elite Pharma's valuation are summarized below:Elite Pharma does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Elite |
Elite Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Elite Pharma's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Elite Pharma.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Elite Pharma on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Elite Pharma or generate 0.0% return on investment in Elite Pharma over 90 days. Elite Pharma is related to or competes with Gilead Sciences, Sanofi ADR, Amgen, Merck, and Novo Nordisk. Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, con... More
Elite Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Elite Pharma's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Elite Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 20.69 | |||
| Value At Risk | (4.88) | |||
| Potential Upside | 4.26 |
Elite Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Elite Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Elite Pharma's standard deviation. In reality, there are many statistical measures that can use Elite Pharma historical prices to predict the future Elite Pharma's volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (0.68) | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | (0.31) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Elite Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Elite Pharma February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 2.44 | |||
| Coefficient Of Variation | (720.71) | |||
| Standard Deviation | 3.89 | |||
| Variance | 15.1 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.68) | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 20.69 | |||
| Value At Risk | (4.88) | |||
| Potential Upside | 4.26 | |||
| Skewness | 1.06 | |||
| Kurtosis | 9.99 |
Elite Pharma Backtested Returns
Elite Pharma secures Sharpe Ratio (or Efficiency) of -0.13, which denotes the company had a -0.13 % return per unit of risk over the last 3 months. Elite Pharma exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Elite Pharma's Standard Deviation of 3.89, mean deviation of 2.44, and Variance of 15.1 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.79, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Elite Pharma will likely underperform. At this point, Elite Pharma has a negative expected return of -0.48%. Please make sure to confirm Elite Pharma's treynor ratio, as well as the relationship between the accumulation distribution and price action indicator , to decide if Elite Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.79 |
Good predictability
Elite Pharma has good predictability. Overlapping area represents the amount of predictability between Elite Pharma time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Elite Pharma price movement. The serial correlation of 0.79 indicates that around 79.0% of current Elite Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.79 | |
| Spearman Rank Test | 0.63 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Elite Pharma reported net income of 8.9 M. This is 97.39% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 98.44% higher than that of the company.
Elite Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elite Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Elite Pharma could also be used in its relative valuation, which is a method of valuing Elite Pharma by comparing valuation metrics of similar companies.Elite Pharma is currently under evaluation in net income category among its peers.
Elite Fundamentals
| Return On Equity | 0.27 | |||
| Return On Asset | 0.0739 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 27.92 M | |||
| Shares Outstanding | 1.01 B | |||
| Shares Owned By Insiders | 17.53 % | |||
| Shares Owned By Institutions | 0.06 % | |||
| Number Of Shares Shorted | 757.07 K | |||
| Price To Earning | 5.21 X | |||
| Price To Book | 1.12 X | |||
| Price To Sales | 0.92 X | |||
| Revenue | 32.26 M | |||
| Gross Profit | 14.8 M | |||
| EBITDA | 7.93 M | |||
| Net Income | 8.9 M | |||
| Cash And Equivalents | 19.78 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 1.39 M | |||
| Debt To Equity | 0.57 % | |||
| Current Ratio | 4.50 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | 6.51 M | |||
| Short Ratio | 0.87 X | |||
| Earnings Per Share | 0.01 X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 43 | |||
| Beta | 0.29 | |||
| Market Capitalization | 38.53 M | |||
| Total Asset | 35.15 M | |||
| Retained Earnings | (147.41 M) | |||
| Working Capital | 14.53 M | |||
| Current Asset | 19.66 M | |||
| Current Liabilities | 5.13 M | |||
| Z Score | 10.6 | |||
| Net Asset | 35.15 M |
About Elite Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elite Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elite Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elite Pharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Elite Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Elite Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elite Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Elite OTC Stock
| 0.85 | ORGN | Origin Materials Earnings Call This Week | PairCorr |
Moving against Elite OTC Stock
| 0.91 | GPOVF | Grupo Carso SAB | PairCorr |
| 0.88 | MRK | Merck Company | PairCorr |
| 0.84 | JNJ | Johnson Johnson | PairCorr |
| 0.83 | WMT | Walmart Common Stock Earnings Call This Week | PairCorr |
| 0.78 | AA | Alcoa Corp | PairCorr |
The ability to find closely correlated positions to Elite Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Elite Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Elite Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Elite Pharma to buy it.
The correlation of Elite Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Elite Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Elite Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Elite Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Elite OTC Stock Analysis
When running Elite Pharma's price analysis, check to measure Elite Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elite Pharma is operating at the current time. Most of Elite Pharma's value examination focuses on studying past and present price action to predict the probability of Elite Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elite Pharma's price. Additionally, you may evaluate how the addition of Elite Pharma to your portfolios can decrease your overall portfolio volatility.